Psyence Biomedical

PBM · NASDAQ

$4.17+$0.045 (+1.09%)TodayMarket closed · Oct 23, 7:47 PM ET

Prev close $4.12

About PBM

Psyence Biomedical Ltd. is a holding company, which engages in the development and commercialization of pharmaceutical products in neurology. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

Employees: 12
Headquarters: TORONTO, Ontario
Listed: Dec 10, 2021
Sector: Health Care
Industry: Biotechnology
Website: psyencebiomed.com

Leadership

Psyence Biomedical executives
Name	Title	Since	Age
Michael Jordaan	—	2021	52
Marc Balkin	—	2021	47
Jurgen Van De Vyver	—	—	34
Simran Aggarwal	—	—	48
Rohit Bodas	—	—	45
Nicole Farb	—	—	42

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.